Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma

JX-594 is an oncolytic vaccinia virus genetically modified to replicate selectively in tumor cells. Metronomic chemotherapy has shown preclinical synergy with oncolytic viruses. We report here the results of the METROMAJX which is a randomized phase II clinical trial investigating the combination of...

Descripción completa

Detalles Bibliográficos
Autores principales: Toulmonde, Maud, Cousin, Sophie, Kind, Michèle, Guegan, Jean-Philippe, Bessede, Alban, Le Loarer, Francois, Perret, Raul, Cantarel, Coralie, Bellera, Carine, Italiano, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585864/
https://www.ncbi.nlm.nih.gov/pubmed/36271420
http://dx.doi.org/10.1186/s13045-022-01370-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585864/
https://www.ncbi.nlm.nih.gov/pubmed/36271420
http://dx.doi.org/10.1186/s13045-022-01370-9

Ejemplares similares